Violet Therapeutics, a Cambridge, MA-based therapeutics company utilizing proprietary platforms for the identification of cell-cell interaction mechanisms, raised $10.6M in Seed funding.
The round was led by Dementia Discovery Fund (DDF), UTEC (University of Tokyo Edge Capital Partners), and was joined by founding investor Mass General Brigham Ventures (MGBV) and Ono Venture Investment. In connection with the financing, Jonathan Behr, PhD, Partner at the DDF, and Atsushi Usami, PhD, Partner and Board Director at the UTEC, have joined Violet’s Board of Directors along with existing investor director, Meredith Fisher at Mass General Brigham Ventures. Shunishiro Matsumoto from Ono Venture Investments joined as an Observer.
The company intends to use the funds to expand operations and its development efforts.
Founded in 2021 by Mass General Brigham Ventures in collaboration with entrepreneurs and scientists from Brigham and Women’s Hospital including Dr. Francisco J. Quintana, Violet Therapeutics is a pre-clinical stage company leveraging platforms to identify, map and mine the cellular connectome at scale. Its initial drug discovery programs are focused on CNS diseases enabled by the novel targets elucidated by their platforms. The company is currently advancing a lead program targeting neuroinflammation, which is being investigated for multiple neurodegenerative indications, including Alzheimer’s disease.
FinSMEs
02/06/2023